Correction To: Placenta-Specific1 (Plac1) Is a Potential Target for Antibody-Drug Conjugate-Based Prostate Cancer Immunotherapy (Scientific Reports, (2017), 7, 1, (13373), 10.1038/S41598-017-13682-9) Publisher Pubmed



Nejadmoghaddam MR^{1, 2} ; Zarnani AH^{3, 4} ; Ghahremanzadeh R² ; Ghods R^{5, 6} ; Mahmoudian J¹ ; Yousefi M² ; Nazari M⁷ ; Ghahremani MH¹ ; Abolhasani M⁸ ; Anissian A⁹ ; Mahmoudi M¹ ; Dinarvand R^{1, 10} Show Affiliations
Source: Scientific Reports Published:2025

Abstract

Correction to: Scientific Reportshttps://doi.org/10.1038/s41598-017-13682-9, published online 17 October 2017 The original version of this Article contains errors in Figure 6a. Due to an error during figure assembly, some panels that are described as representative of different conditions are partially overlapping: subpanels relating to LNCaP cells in the No treatment and Anti-PLAC1 antibody conditions; subpanels relating to DU145 cells in the No treatment, Anti-PLAC1 antibody, and Free SN38 conditions. subpanels relating to LNCaP cells in the No treatment and Anti-PLAC1 antibody conditions; subpanels relating to DU145 cells in the No treatment, Anti-PLAC1 antibody, and Free SN38 conditions. Additionally, there are errors in the antibody concentrations stated in the figure legend. The updated Figure 6 and accompanying legend appear below. (Figure presented.) In vitro cytotoxicity assessment of anti-PLAC1-ADC. Prostate cancer cells and LS180, as negative cell control, were treated with at least 2.5 µg/mL anti-PLAC1 antibody or 2.5 µg/mL of anti-PLAC1-ADC, equivalent concentration of free SN38, or remained untreated. Cell morphology was visualized after 48 h under microscope (a). LNCaP cells were treated with different concentrations of free SN38 or equivalent concentrations of anti-PLAC1-ADC or isotype-matched-ADC and the rate of cell cytotoxicity was assessed by Calcein AM fluorometric assay. It is important to note that the highest concentration of antibody (10 µg/mL) was used in some control samples (e.g., DU145 cells) to confirm the absence of toxic effects on the cells, while the ADC treated cells at a concentration of 2.5 µg/mL exhibited clear toxicity. (b). Calcein AM-labeled LNCaP cells were inspected under fluorescent microscope 36 h after treatment with 2.5 µg/mL anti-PLAC1-ADC, isotype-matched-ADC, anti-PLAC1 antibody or equivalent concentration of free SN38 (c). IC50 values for free SN38 and anti-PLAC1-ADC were determined using the Prism software as described in materials and methods (d). Data were generated from four independent experiments. *Anti-PLAC1-ADC vs. free SN38, ϕanti-PLAC1-ADC vs. isotype-matched-ADC, * or ϕp < 0.05, ** or ϕϕp < 0.01, *** or ϕϕϕp < 0.001, **** or ϕϕϕϕp < 0.0001. © The Author(s) 2025.